Released Feb 25, 2025, before the open
10-K filed Feb 25, 2025, 56 days after period end · 0000950170-25-026066
Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$215.66M$215.66M derived+7.6% vs Q4 2023+9.7% vs Q3 2024
Net Income-$29.15M-$29.15M derivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$148,841,000+8.9%
Operating Incomederived-$11,477,000N/M
Operating Cash Flowderived$23,730,000N/M
Free Cash Flowderived$14,063,000N/M
Margins · derived
Gross margin69.0%+0.8 pt vs Q4 2023
Operating margin-5.3%+3.8 pt vs Q4 2023
Net margin-13.5%−2.5 pt vs Q4 2023
What the release said
The release
Same quarter
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Revenue | $215.66M | $200.42M | $122.23M | $125.06M |
| Net Income | -$29.15M | -$22.17M | -$7.06M | -$32.81M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR